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Diisononyl phthalate (DINP) is a complex
mixture of branched-chain dialkyl phthalate
isomers, predominantly containing nine car-
bons in the alkyl chain. DINP is used primar-
ily as a plasticizer in polyvinyl chloride plastics
(Abe et al. 2003) and is widely used in auto-
motives, building materials, consumer prod-
ucts, and toys [Center for the Evaluation of
Risks to Human Reproduction (CERHR)
2000; Kavlock et al. 2002].
In rats, DINP shows antiandrogenic activ-
ity (Gray et al. 2000). Speciﬁcally, nipple reten-
tion and testis atrophy after perinatal exposure
to 750 mg/kg DINP have been observed in
male rats (Gray et al. 2000). It appears that
DINP, like di(2-ethylhexyl) phthalate (DEHP),
a widely used phthalate, alters sexual differenti-
ation of the male rat by inhibiting testicular
testosterone synthesis (Gray et al. 2000).
Furthermore, evidence has shown that oral
exposure to DINP causes liver and kidney toxi-
city in adult rats and mice (Kaufmann et al.
2002). The liver effects are generally consistent
with those associated with peroxisome prolifera-
tion (Kaufmann et al. 2002).
DINP biomonitoring to measure exposure
in humans is of interest because of the poten-
tial adverse health effects of DINP. More
important, children may be exposed to higher
levels of DINP than adults because infants and
small children mouth toys and other articles
that can contain DINP (Kavlock et al. 2002).
Because DINP is not covalently bound to the
plastics, it can migrate into saliva and be swal-
lowed (Kavlock et al. 2002). In previous stud-
ies the hydrolytic monoester of DINP,
monoisononyl phthalate (MINP), has been
used for human exposure assessment of DINP
[Centers for Disease Control and Prevention
(CDC) 2005; Silva et al. 2004a]. However, the
frequency of detection of MINP was very low
compared with other phthalate metabolites.
The low frequency of detection of MINP in
human populations may be attributable, at
least in part, to the fact that MINP further
metabolizes to form oxidative metabolites
before being excreted in urine. Although the
metabolism of DEHP (Albro 1986; Koch et al.
2004, 2005a; Silva et al. 2006b, 2006c) and
di-n-octyl phthalate (DnOP) (Albro and
Moore 1974; Calafat et al. 2006; Silva et al.
2005) in rodents and humans is relatively well
known, the metabolism of DINP has been less
studied (McKee et al. 2002).
In rodents, MINP was found to metabo-
lize to unidentiﬁed oxidative products (McKee
et al. 2002). Recently, several urinary oxidative
metabolites of DINP were identified and
detected at much higher concentrations than
MINP in DINP-dosed rats (Silva et al. 2006a).
It was postulated that these metabolites could
be used as biomarkers of exposure to DINP in
humans (Silva et al. 2006a). In this study,
MINP and three of these oxidative metabo-
lites, mono(carboxyisooctyl) phthalate
(MCIOP), mono(hydroxyisononyl) phthalate
(MHINP), and mono(oxoisononyl) phthalate
(MOINP) (Figure 1), were measured in
129 human urine samples from adults with
no known exposure to DINP. As in rodents,
in this group of adults the frequency and the
magnitude of detection were significantly
higher for the oxidative metabolites than
for MINP.
Materials and Methods
We purchased mono(2-ethyl-5-hydroxyhexyl)
phthalate (MEHHP), mono(2-ethyl-5-
oxohexyl) phthalate (MEOHP), mono(2-
ethylhexyl) phthalate (MEHP), mono-3-
methyl-5-dimethylhexyl phthalate (MINP),
13C4-MEHP, 13C4-MEHHP, 13C4-MEOHP,
13C4-MINP, and 13C4 -4-methylumbel-
liferone (13C4-MeUmb) from Cambridge
Isotopes Laboratories Inc. (Andover, MA).
Mono(2-ethyl-5-carboxypentyl) phthalate
(MECPP) and D4-MECPP were gifts
from J. Angerer (University of Erlangen,
Nuremberg, Germany). HPLC-grade ace-
tonitrile and water were purchased from Tedia
(Fairfield, OH), and MeUmb and its glu-
curonide (MeUmb-glu) were purchased
from Sigma Chemical Co. (St. Louis, MO).
β-Glucuronidase (Escherichia coli-K12) was pur-
chased from Roche Biomedical (Mannheim,
Germany). Stock solutions of standards
(MEHP, MEOHP, MEHHP, and MeUmb)
and internal standards (13C4-MEHP, 13C4-
MEHHP, 13C4-MEOHP, and 13C4-MeUmb)
were prepared in acetonitrile. 13C4-MEOHP
was used as the internal standard for MOINP,
D4-MECPP was used as the internal standard
for MCIOP, and 13C4-MEHHP was used as
the internal standard for MHINP.
Urine samples were collected by each study
participant directly into a phthalate-free
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Diisononyl phthalate (DINP) is a complex mixture of predominantly nine-carbon branched-
chain dialkyl phthalate isomers. Similar to di(2-ethylhexyl) phthalate, a widely used phthalate,
DINP causes antiandrogenic effects on developing rodent male fetuses. Traditionally, assessment
of human exposure to DINP has been done using monoisononyl phthalate (MINP), the
hydrolytic metabolite of DINP, as a biomarker. However, MINP is only a minor urinary
metabolite of DINP. Oxidative metabolites, including mono(carboxyisooctyl) phthalate
(MCIOP), mono(oxoisononyl) phthalate (MOINP), and mono(hydroxyisononyl) phthalate
(MHINP) are the major urinary metabolites in DINP-dosed rats. The urinary concentrations of
MINP, MCIOP, MOINP, and MHINP were measured in 129 adult anonymous human volun-
teers with no known exposure to DINP. Although MINP was not present at detectable levels in
any of the samples analyzed, MCIOP, MHINP, and MOINP were detected in 97, 100, and 87%
of the urine samples at geometric mean levels equal to 8.6, 11.4, and 1.2 ng/mL, respectively.
The concentrations of all three oxidative metabolites were highly correlated with each other
(p < 0.0001), which conﬁrms a common precursor. MCIOP was excreted predominantly as a free
species, whereas MOINP was excreted mostly in its glucuronidated form. The percentage of
MHINP excreted either glucuronidated or in its free form was similar. The signiﬁcantly higher
frequency of detection and urinary concentrations of oxidative metabolites than of MINP suggest
that these oxidative metabolites are better biomarkers of exposure assessment of DINP than is
MINP. Therefore, we concluded that the prevalence of human exposure to DINP is under-
estimated by using MINP as the sole DINP urinary biomarker. Key words: biomarkers,
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[Online 27 March 2006]prescreened urine cup. The analytical method
for measuring DINP oxidative metabolites in
urine was adapted from previously published
methods (Blount et al. 2000; Silva et al. 2003,
2004b). Brieﬂy, the urine samples (1 mL) were
spiked with an internal standard solution 
containing 13C4-MEHP, 13C4-MEOHP,
13C4-MEHHP, D4-MECPP, 13C4-MINP,
and 4-MeUmb. MeUmb-glu was added to
evaluate the completion of the deglucuronida-
tion reaction with β-glucuronidase. Phthalate
monoester metabolites were extracted by auto-
mated solid-phase extraction (SPE) using a
commercial SPE system (Zymark Corp.,
Hopkinton, MA) after enzymatic hydrolysis.
The metabolites in the urine extract were chro-
matographically resolved by high-performance
liquid chromatography (HPLC) using a
Surveyor HPLC system (ThermoFinnigan,
San Jose, CA) equipped with a Betasil phenyl
HPLC column (3 µm, 100 mm × 2.1 mm;
ThermoHypersil-Keystone, Bellefonte, PA)
using a nonlinear water:acetonitrile solvent gra-
dient. The metabolites were detected by nega-
tive ion electrospray ionization tandem mass
spectrometry using a ThermoFinnigan TSQ
Quantum triple quadrupole mass spectrometer
(ThermoFinnigan). For the measurement of
the unconjugated metabolites, we eliminated
treatment with β-glucuronidase. Under our
experimental conditions, the isomeric metabo-
lites of DINP were not chromatographically
resolved and eluted as broad peaks. The entire
area under the peak encompassing all isomers
was integrated for quantiﬁcation. The limits of
detection (LODs) were 0.25 ng/mL for
MOINP, MHINP, and MCIOP. The LOD
for MINP was 0.36 ng/mL. Oxidative metabo-
lism is an enzymatically mediated reaction.
Therefore, oxidative metabolites cannot result
from potential contamination with DINP dur-
ing sampling, storage, or analysis.
Statistical analysis of the data was per-
formed using the Statistical Analysis System
(SAS) software (SAS Institute Inc., Cary, NC).
Samples with values below the LOD were
assigned a concentration equal to the LOD
divided by the square root of 2 for the statisti-
cal analyses (Hornung and Reed 1990).
Statistical signiﬁcance was set at p < 0.05.
Subjects. The urine samples analyzed for
this study were collected speciﬁcally for analysis
of phthalate metabolites in 2005 from a demo-
graphically diverse group of 129 U.S. adults of
both sexes with no documented exposure to
DINP. No personal information from the sub-
jects was available. Samples were collected
between 0800 hr and 1700 hr and were not
necessarily ﬁrst morning voids. The study pro-
tocol was reviewed and approved by the CDC
Human Subjects Institutional Review Board. A
waver for informed consent for this project was
requested under 45 CFR 46.116(d) (Code of
Federal Regulations 2005).
Results and Discussion
Although DINP is a less potent inducer of
peroxisomal proliferation than DEHP
(McKee et al. 2000), DINP exerts antiandro-
genic effects similar to that of DEHP in
DINP-dosed rats (Gray et al. 2000). The
effects of DINP exposure in humans are not
currently known.
Phthalates with long alkyl side chains, such
as DEHP and DnOP, metabolize extensively
before being excreted in urine both in rodents
and humans (Albro 1986; Albro and Moore
1974; Koch et al. 2004, 2005b; Silva et al.
2005). Similarly, in rats administered DINP,
some MINP was excreted in urine, but oxida-
tive metabolites of MINP, MHINP, MCIOP,
and MOINP were excreted as the major uri-
nary metabolites (Silva et al. 2006a).
We measured the urinary concentrations of
MINP, MHINP, MCIOP, and MOINP in
129 human adults. We observed a wide range
of exposures to DINP (Table 1). MHINP was
present in all samples tested at concentrations
ranging from 1.4 to 202.7 ng/mL, with 5% of
the samples having > 43.7 ng/mL (Table 1).
Similarly, MCIOP was detected in 97% of the
samples tested at levels ranging from < LOD to
310.8 ng/mL. MOINP was detected in 87%
of the samples at levels ranging from < LOD to
201.7 ng/mL (Table 1). The geometric mean
concentrations of MHINP, MCIOP, and
MOINP were 11.4, 8.6, and 1.2 ng/mL,
respectively. Interestingly, we did not detect
MINP in any of the samples analyzed.
In rats dosed with DINP, the major
metabolite excreted in urine was MCIOP (Silva
et al. 2006a). By contrast, in this study popula-
tion, MHINP was excreted as the major uri-
nary metabolite (Table 1). Although three
oxidative metabolites of DINP were present in
all samples analyzed, the urinary concentrations
of these metabolites were lower than the struc-
turally related DEHP metabolites MEHHP,
MEOHP, and MECPP, also measured in this
population (Silva et al. 2006b) (Figure 2). In
humans, the urinary concentrations of
MEHHP, MEOHP, MECPP, and MEHP
represent about 75% of the DEHP dose (Koch
et al. 2004, 2005b). The fraction of DINP
excreted in urine as MHINP, MOINP,
MCIOP, and MINP is not presently known.
MCIOP, MOINP, and MHINP are DINP biomarkers
Environmental Health Perspectives • VOLUME 114 | NUMBER 8 | August 2006 1159
Table 1. Urinary levels (ng/mL) of DINP metabolites in a group of 129 U.S. adults. 
Urinary DINP  Selected percentiles Geometric Frequency of
metabolitea n 10th 25th 50th 75th 90th 95th meanb detection (%)
MCIOP
Total 129 2.0 3.9 8.4 18.3 27.3 46.2 7.8 97
Freec 82 2.0 2.9 5.1 11.6 22.8 1.5 6.1 98
MHINP
Total 129 2.6 5.4 13.2 23.2 40.2 43.7 11.4 100
Freec 82 1.8 2.9 5.8 9.1 15.5 20.1 5.4 100
MOINP
Total 129 < LOD 0.5 1.2 2.4 5.0 6.6 1.2 87
Freec 82 < LOD < LOD < LOD 0.3 0.7 1.3 NA 30
MINP
Freec 129 < LOD < LOD < LOD < LOD < LOD < LOD < LOD 0
Total 82 < LOD < LOD < LOD < LOD < LOD < LOD < LOD 0
NA, applicable: the geometric mean was calculated only if the frequency of detection was ≥ 60%. 
aD4-MECPP was used as the internal standard for MCIOP. 13C4-MEOHP was used as the internal standard for MOINP.
13C4-MEHHP and 13C4-MINP were used as the internal standards for MHINP and MINP, respectively. bLOD/√
–
2 was used
for the statistical computations if the concentration was below the LOD. LODs were 0.36 ng/mL (MINP) and 0.25 ng/mL
(MCIOP, MHINP, and MOINP). cOnly 82 samples were available in sufﬁcient quantities to determine the concentrations of
free metabolites.
Figure 1. DINP metabolites proposed as biomarkers for exposure assessment to DINP in humans.
Structures shown are for only one of the potential isomers.
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Figure 2. Median levels of DINP and DEHP metabo-
lites in a group of 129 U.S. adults. For concentra-
tions < LOD, a value of LOD/√
–
2 was used for the
statistical computations.Based on similar physicochemical properties
and metabolism between DINP and DEHP
(Koch et al. 2004, 2005b; Silva et al. 2006b,
2006c), the lower concentrations of DINP
oxidative metabolites than of DEHP oxidative
metabolites in this group of adults suggest that
environmental exposures to DINP may be
lower than the exposure to DEHP. However,
because DINP is a mixture of isomers, it is also
possible that the prevalence of exposure to
DINP is underestimated by measuring only
these three oxidative metabolites. Furthermore,
the elimination half-life of the oxidative
metabolites of DINP is presently unknown.
Therefore, the differences in urinary concentra-
tions observed among DINP oxidative metabo-
lites and their DEHP counterparts may also
reﬂect differences in toxicokinetic parameters.
Because all three DINP metabolites result
from the same parent compound, their urinary
concentrations were highly correlated with
each other, with correlation coefﬁcients varying
from 0.73 to 0.83 (p < 0.001; Figure 3), simi-
lar to previous findings regarding DEHP
metabolites (Barr et al. 2003; Kato et al. 2004;
Koch et al. 2004, 2005b).
Glucuronidation not only facilitates urinary
excretion of phthalate metabolites but may also
reduce their potential biological activity if the
putative biologically active species is the free
metabolite. We measured both total and free
urinary concentrations of MHINP, MOINP,
and MCIOP and found that although MCIOP
mostly excreted in its free form, MOINP
excreted mostly glucuronidated. The percent-
age of MHINP excreted either as a conjugate or
free form was similar (Figure 4). Furthermore,
the concentration of the glucuronidated form
of the metabolites increased with increasing lev-
els of the total metabolite concentrations, indi-
cating the absence of enzyme saturation at
environmental exposure levels (Figure 5).
In summary, we measured the urinary con-
centrations of three oxidative metabolites of
DINP (MCIOP, MHINP, and MOINP)
and the hydrolytic metabolite MINP in
129 anonymous adults. The oxidative metabo-
lites were present in all samples tested, and
their urinary concentrations were highly corre-
lated with each other. By contrast, the
hydrolytic monoester MINP was not detected
in any of the samples. The most abundant
DINP urinary metabolites were the ω and ω-1
oxidative metabolites, MCIOP and MHINP,
Silva et al.
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Figure 4. Frequency of detection of free urinary DINP oxidative metabolites: (A) MCIOP, (B) MHINP, and (C) MOINP. 
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Figure 3. Correlation analyses of urinary MCIOP, MHINP, and MOINP. R represents Pearson correlation coefﬁcient. Levels below the LOD were excluded in the
analysis: (A) R = 0.83, p < 0.0001; (B) R = 0.76, p < 0.0001; (C) R = 0.73, p < 0.0001.
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Figure 5. Correlation analyses of the glucuronide-conjugated DINP metabolites and the total (free and glucuronidated). Levels < LOD were eliminated in the
graphical representations. (A) R = 0.90, p < 0.0001; (B) R = 0.90, p < 0.0001; (C) R = 0.98, p < 0.0001.MCIOP, MOINP, and MHINP are DINP biomarkers
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respectively. MCIOP was excreted in urine
predominantly in its free form, whereas
MOINP was excreted glucuronidated. The
signiﬁcantly higher frequency of detection and
urinary levels of oxidative metabolites than of
MINP conﬁrm the validity of these oxidative
metabolites as biomarkers for DINP exposure
assessment. More important, these data suggest
that exposure to DINP is widespread and that
it has been underestimated by using MINP as
the sole DINP urinary biomarker.
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CORRECTION
In Figure 5, values for urinary MOINP glu-
curonide on the y-axis have been modiﬁed
from the original manuscript published
online. The corrected values are 0.1, 1, 10,
100, and 1,000. The original values were
0.1, 1, 10, and 100. 